a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number			10708315	
Filing Date			2005-08-25	
First Named Inventor David		David	d E. Mekas	
Art Unit			1772	
Examiner Name Alicia		Alicia	Ann Chevalier	
Attorney Docket Number		r	MASL-31	

				U.S.	PATENTS	Remove		
Examiner Initial*			Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	6991841	B2	2006-01-31	Cowelchuk et al.			
	2	6983967	B2	2006-03-13	Scheidmantel et al.			
	3	6955392 B2 2005-10-18		2005-10-18	Dry			
	4	6929309	B1	2005-08-16	Radu et al.			
	5	6899373	B2	2005-05-31	Km			
	6	6899363	B2	2005-05-31	Dry			
	7	6837544	B2	2005-01-04	Bornchen et al.			
	8	6793181	В1	2004-09-21	Hallock			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Art Unit		10708315	
			2005-08-25	
			E. Mekas	
			1772	
			Ann Chevalier	
			MASL-31	

	9	6742630	B2	2004-06-01	Zimmerman et al.			
	10	6706462	B2	2004-03-23	Pokorzynski et al.			
	11	6308488	B1	2001-10-30	Hoshino			
	12	6186582	B1	2001-02-13	Beckmann			
	13	6070905		2000-06-06	Renault			
	14	5626382		1997-05-06	Johnson et al.			
	15	5527084		1996-06-18	Scherf			
	16	5395135		1995-03-07	Lm et al.			
	17	5297842		1994-03-29	Hayasshi			
	18	6453535	B1	2002-09-24	Nicholas			
If you wis	h to a	dd additional U.S. Pater			ease click the Add button.	Add		
	U.S.PATENT APPLICATION PUBLICATIONS Remove							

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10708315	
Filing Date		2005-08-25	
First Named Inventor David		E. Mekas	
Art Unit		1772	
Examiner Name Alicia		Ann Chevalier	
Attorney Docket Number		MASI -31	

Examiner Initial*	Cite No	Publication Number		Publication Name of Patentee or Applicant Re		Relev	Pages,Columns,Lines where Relevant Passages or Releva Figures Appear				
	1										
If you wis	h to a	dd additional U.S. Publ	shed Ap	plication	citatio	ı n information p	please click the Ad	d butto	n. Add		
				FOREIG	GN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite Foreign Document Number ³				Kind Code ⁴	Kind Publication	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	button	Add		_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc),					ТБ
	1										_

EYAMINED SIGNATURE Date Considered Examiner Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

1 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3) 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10708315
Filing Date		2005-08-25
First Named Inventor David		E. Mekas
Art Unit		1772
Examiner Name Alicia		Ann Chevalier
Attorney Docket Number		MASL-31

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):	
---	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a deepin patient office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c).

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David W. Dorton/	Date (YYYY-MM-DD)	2006-03-14
Name/Print	David W. Dorton	Registration Number	51625

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 Gard 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandris, V.S. 2213.1-450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2. 2213.1-450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (ii.e., GSA).
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.